Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation.

Chu G, Seelig J, Trinks-Roerdink EM, van Alem AP, Alings M, van den Bemt B, Boersma LV, Brouwer MA, Cannegieter SC, Ten Cate H, Kirchhof CJ, Crijns HJ, van Dijk EJ, Elvan A, van Gelder IC, de Groot JR, den Hartog FR, de Jong JS, de Jong S, Klok FA, Lenderink T, Luermans JG, Meeder JG, Pisters R, Polak P, Rienstra M, Smeets F, Tahapary GJ, Theunissen L, Tieleman RG, Trines SA, van der Voort P, Geersing GJ, Rutten FH, Hemels ME, Huisman MV

Open source

DOI
10.1136/bmjopen-2019-036220
Published
2020 Aug 24
Container
BMJ open
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2019-036220,
  title = {Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation.},
  author = {Chu G and Seelig J and Trinks-Roerdink EM and van Alem AP and Alings M and van den Bemt B and Boersma LV and Brouwer MA and Cannegieter SC and Ten Cate H and Kirchhof CJ and Crijns HJ and van Dijk EJ and Elvan A and van Gelder IC and de Groot JR and den Hartog FR and de Jong JS and de Jong S and Klok FA and Lenderink T and Luermans JG and Meeder JG and Pisters R and Polak P and Rienstra M and Smeets F and Tahapary GJ and Theunissen L and Tieleman RG and Trines SA and van der Voort P and Geersing GJ and Rutten FH and Hemels ME and Huisman MV},
  year = {2020},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2019-036220},
  url = {https://doi.org/10.1136/bmjopen-2019-036220}
}

RIS

TY  - JOUR
TI  - Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation.
AU  - Chu G
AU  - Seelig J
AU  - Trinks-Roerdink EM
AU  - van Alem AP
AU  - Alings M
AU  - van den Bemt B
AU  - Boersma LV
AU  - Brouwer MA
AU  - Cannegieter SC
AU  - Ten Cate H
AU  - Kirchhof CJ
AU  - Crijns HJ
AU  - van Dijk EJ
AU  - Elvan A
AU  - van Gelder IC
AU  - de Groot JR
AU  - den Hartog FR
AU  - de Jong JS
AU  - de Jong S
AU  - Klok FA
AU  - Lenderink T
AU  - Luermans JG
AU  - Meeder JG
AU  - Pisters R
AU  - Polak P
AU  - Rienstra M
AU  - Smeets F
AU  - Tahapary GJ
AU  - Theunissen L
AU  - Tieleman RG
AU  - Trines SA
AU  - van der Voort P
AU  - Geersing GJ
AU  - Rutten FH
AU  - Hemels ME
AU  - Huisman MV
PY  - 2020
JO  - BMJ open
DO  - 10.1136/bmjopen-2019-036220
UR  - https://doi.org/10.1136/bmjopen-2019-036220
ER  - 

APA

G, C., J, S., EM, T., AP, V. A., M, A., B, V. D. B., LV, B., MA, B., SC, C., H, T. C., CJ, K., HJ, C., EJ, V. D., A, E., IC, V. G., JR, D. G., FR, D. H., JS, D. J., S, D. J., FA, K., T, L., JG, L., JG, M., R, P., P, P., M, R., F, S., GJ, T., L, T., RG, T., SA, T., P, V. D. V., GJ, G., FH, R., ME, H., & MV, H. (2020). Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation.. BMJ open. https://doi.org/10.1136/bmjopen-2019-036220

Source records